Oncogenic signaling of growth factor receptors in cancer : : mechanisms and therapeutic opportunities / / edited by Anica Dricu.
At the molecular level, the activation of growth factor receptors (GFRs) induces a mitogenic response and maintains cancer cell growth. The majority of malignant diseases are related to aberrant intra- and intercellular communication, associated with the GFR-mediated pathways. Moreover, the evasion...
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | Basel, Switzerland : : MDPI - Multidisciplinary Digital Publishing Institute,, 2023. |
Year of Publication: | 2023 |
Language: | English |
Physical Description: | 1 online resource (202 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993600116104498 |
---|---|
ctrlnum |
(CKB)4960000000467902 (NjHacI)994960000000467902 (EXLCZ)994960000000467902 |
collection |
bib_alma |
record_format |
marc |
spelling |
Oncogenic signaling of growth factor receptors in cancer : mechanisms and therapeutic opportunities / edited by Anica Dricu. Oncogenic Signaling of Growth Factor Receptors in Cancer Basel, Switzerland : MDPI - Multidisciplinary Digital Publishing Institute, 2023. 1 online resource (202 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on publisher supplied metadata and other sources. At the molecular level, the activation of growth factor receptors (GFRs) induces a mitogenic response and maintains cancer cell growth. The majority of malignant diseases are related to aberrant intra- and intercellular communication, associated with the GFR-mediated pathways. Moreover, the evasion of apoptotic signals and the requirement of angiogenesis were also found to be of fundamental importance for tumor progression and metastasis. In this context, a high expression of GFRs aids blood vessel formation, cell migration, and the inhibition of apoptosis. GFR-directed therapy that would theoretically selectively kill malignant cells and reduce the toxicity associated with nonselective conventional chemotherapy may be a promising treatment for cancer. Many intracellular proteins involved in GFR signal transduction can also function as oncogenes. Mutations affecting key proteins in the RAS/MAPK and PI3K/AKT pathways are known to be crucial in maintaining the malignancy of different types of cancers. This information has guided the development of compounds designed to target one or more of these pathways in cancer cells. Even though there have been important advances in our understanding of GFRs and their signaling, certain essential information is still lacking, and these membrane receptors are still being laboriously studied by several research groups, to find therapeutic solutions to unmet medical needs. Cancer cells Growth. 3-0365-7337-2 Dricu, Anica, editor. |
language |
English |
format |
eBook |
author2 |
Dricu, Anica, |
author_facet |
Dricu, Anica, |
author2_variant |
a d ad |
author2_role |
TeilnehmendeR |
title |
Oncogenic signaling of growth factor receptors in cancer : mechanisms and therapeutic opportunities / |
spellingShingle |
Oncogenic signaling of growth factor receptors in cancer : mechanisms and therapeutic opportunities / |
title_sub |
mechanisms and therapeutic opportunities / |
title_full |
Oncogenic signaling of growth factor receptors in cancer : mechanisms and therapeutic opportunities / edited by Anica Dricu. |
title_fullStr |
Oncogenic signaling of growth factor receptors in cancer : mechanisms and therapeutic opportunities / edited by Anica Dricu. |
title_full_unstemmed |
Oncogenic signaling of growth factor receptors in cancer : mechanisms and therapeutic opportunities / edited by Anica Dricu. |
title_auth |
Oncogenic signaling of growth factor receptors in cancer : mechanisms and therapeutic opportunities / |
title_alt |
Oncogenic Signaling of Growth Factor Receptors in Cancer |
title_new |
Oncogenic signaling of growth factor receptors in cancer : |
title_sort |
oncogenic signaling of growth factor receptors in cancer : mechanisms and therapeutic opportunities / |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute, |
publishDate |
2023 |
physical |
1 online resource (202 pages) |
isbn |
3-0365-7336-4 3-0365-7337-2 |
callnumber-first |
R - Medicine |
callnumber-subject |
RC - Internal Medicine |
callnumber-label |
RC267 |
callnumber-sort |
RC 3267 O536 42023 |
illustrated |
Not Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
616 - Diseases |
dewey-full |
616.99407 |
dewey-sort |
3616.99407 |
dewey-raw |
616.99407 |
dewey-search |
616.99407 |
work_keys_str_mv |
AT dricuanica oncogenicsignalingofgrowthfactorreceptorsincancermechanismsandtherapeuticopportunities AT dricuanica oncogenicsignalingofgrowthfactorreceptorsincancer |
status_str |
n |
ids_txt_mv |
(CKB)4960000000467902 (NjHacI)994960000000467902 (EXLCZ)994960000000467902 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Oncogenic signaling of growth factor receptors in cancer : mechanisms and therapeutic opportunities / |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796653161077800960 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02439nam a2200289 i 4500</leader><controlfield tag="001">993600116104498</controlfield><controlfield tag="005">20230623202809.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230623s2023 sz o 000 0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-0365-7336-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4960000000467902</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)994960000000467902</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994960000000467902</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC267</subfield><subfield code="b">.O536 2023</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.99407</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Oncogenic signaling of growth factor receptors in cancer :</subfield><subfield code="b">mechanisms and therapeutic opportunities /</subfield><subfield code="c">edited by Anica Dricu.</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Oncogenic Signaling of Growth Factor Receptors in Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel, Switzerland :</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute,</subfield><subfield code="c">2023.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (202 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">At the molecular level, the activation of growth factor receptors (GFRs) induces a mitogenic response and maintains cancer cell growth. The majority of malignant diseases are related to aberrant intra- and intercellular communication, associated with the GFR-mediated pathways. Moreover, the evasion of apoptotic signals and the requirement of angiogenesis were also found to be of fundamental importance for tumor progression and metastasis. In this context, a high expression of GFRs aids blood vessel formation, cell migration, and the inhibition of apoptosis. GFR-directed therapy that would theoretically selectively kill malignant cells and reduce the toxicity associated with nonselective conventional chemotherapy may be a promising treatment for cancer. Many intracellular proteins involved in GFR signal transduction can also function as oncogenes. Mutations affecting key proteins in the RAS/MAPK and PI3K/AKT pathways are known to be crucial in maintaining the malignancy of different types of cancers. This information has guided the development of compounds designed to target one or more of these pathways in cancer cells. Even though there have been important advances in our understanding of GFRs and their signaling, certain essential information is still lacking, and these membrane receptors are still being laboriously studied by several research groups, to find therapeutic solutions to unmet medical needs.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cancer cells</subfield><subfield code="x">Growth.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-7337-2</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dricu, Anica,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-07-06 03:22:17 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2023-05-13 19:27:32 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5345685540004498&Force_direct=true</subfield><subfield code="Z">5345685540004498</subfield><subfield code="b">Available</subfield><subfield code="8">5345685540004498</subfield></datafield></record></collection> |